Mibefradil: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | '''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]]. It belongs to a group known as [[calcium channel blockers]]. | ||
It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref> | |||
On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref> | |||
==References=={{Reflist}} | |||
{{Membrane transport modulators}} | |||
[[Category:Calcium channel blockers]][[Category:Withdrawn drugs]][[Category:Benzimidazoles]][[Category:Organofluorides]][[Category:Ethers]][[Category:Amines]][[Category:Methyl esters]] | |||
[[Category: Selective calcium channel blockers with mainly vascular effects]][[Category: Dihydropyridine derivatives]][[Category: Cardiovascular Drugs]][[Category: Drug]] | |||
[[Category:Drugs]] | |||
Revision as of 15:21, 23 July 2014
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers. It is nonselective.[1] On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]
==References==
- ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ↑ Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html